The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Anteris or the Company ) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart ...

Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.

Patients in Northwest Georgia and Southeast Tennessee are accessing care once found only in larger metro areas — thanks to ...

Our initial experience with the DurAVR ® THV System has been very positive, and we look forward to providing definitive comparative evidence which could transform patient care.” “With the first ...

A team of researchers led by Xiaoguang Dong, assistant professor of mechanical and biomedical engineering at Vanderbilt ...